BriaCell Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is August - July.

Millions USD. Fiscal year is Aug - Jul.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Oct '25 Oct 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022	Jul '21 Jul 31, 2021	Jul '20 Jul 31, 2020
Net Income	-24.28	-4.93	-20.3	-26.84	-13.82	-4.02
Depreciation & Amortization	-	0.08	0.02	0.02	0.02	0.02
Stock-Based Compensation	0.99	1.8	2.19	3.07	1.97	0
Other Adjustments	-0.11	-28.14	-2.12	11.66	6.36	0.08
Change in Receivables	-	-0.73	0.01	-0.01	0.01	-0.02
Changes in Other Operating Activities	1.46	7.79	-3.54	-0.38	-2.29	2.69
Operating Cash Flow	-25.52	-24.13	-23.74	-12.48	-7.75	-1.27
Capital Expenditures	-	-0.46	-	-	-	-
Purchases of Investments	-0.31	-0.23	-	-	-	-
Investing Cash Flow	-0.31	-0.68	-	-	-	-
Short-Term Debt Issued	-	-	-	-	-	0.41
Short-Term Debt Repaid	-	-	-	-	-0.24	-
Net Short-Term Debt Issued (Repaid)	-	-	-	-	-0.24	0.41
Long-Term Debt Issued	-	-	-	-	0.22	-
Long-Term Debt Repaid	-	-	-	-	-0.31	-0.39
Net Long-Term Debt Issued (Repaid)	-	-	-	-	-0.09	-0.39
Issuance of Common Stock	31.07	4.42	4	6.51	65.33	1.15
Repurchase of Common Stock	-	-	-0.05	-10.17	-	-
Net Common Stock Issued (Repurchased)	31.07	4.42	3.95	-3.66	65.33	1.15
Other Financing Activities	-	-	-	-0.08	-	-
Financing Cash Flow	31.89	4.42	3.95	-3.74	65	1.17
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-	-	-	-	-	-0.04
Net Cash Flow	6.06	-20.39	-19.79	-16.23	57.25	-0.09
Beginning Cash & Cash Equivalents	-	21.25	41.04	57.27	0.02	0.16
Ending Cash & Cash Equivalents	6.06	0.86	21.25	41.04	57.27	0.02
Free Cash Flow	-25.52	-24.58	-23.74	-12.48	-7.75	-1.27
Free Cash Flow Per Share	-37.74	-224.09	-228.03	-120.86	-257.22	-265.99
Levered Free Cash Flow	-21.13	2.62	-23.82	-27.2	-16.42	-1.38
Unlevered Free Cash Flow	-21.66	-25.92	-26.79	-15.65	-9.25	-1.24

Updated Oct 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.